Genprex, Inc.

45 articles with Genprex, Inc.

• Genprex to Present at the MicroCap Rodeo Investor Conference

  10/9/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.

• Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support

  10/7/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy.

• Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019

  9/18/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the Singular Research Midwestern Values Conference on September 19, 2019 via webcast.

• CORRECTING and REPLACING Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/7/2019

  Date, time and room of presentation of release dated September 5, 2019, should read: Monday, September 9, 2019, from 12:30-12:55 p.m. EDT in Adams.

• Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/5/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019 in New York City.

• Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

  9/3/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

• Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference

  8/21/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019.

• Genprex Demonstrates Growth and Expansion Through Recent Achievements

  8/13/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex™ immunogene therapy, to commercialization.

• Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

  8/6/2019

  Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

• Genprex Begins Next Phase of Drug Branding Program

  7/31/2019

  Company submits non-proprietary drug name selections to United States Adopted Names Council

• Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

  5/21/2019

  Genprex, Inc., a clinical-stage gene therapy company, announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019.

• Genprex Retains Addison Whitney for Drug Nomenclature Branding

  5/8/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney.

• Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

  4/8/2019

  TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade

• Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

  4/1/2019

  Today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.

• Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

  3/14/2019

  Alliance for Regenerative Medicines’ Seventh Annual Investors Conference

• Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

  2/19/2019

  Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex

• Genprex to Present at NobleConXV in Fort Lauderdale, Florida

  1/23/2019

  Noble Capital Markets' Fifteenth Annual Investor / Equity Conference

• Genprex to Present at Biotech Showcase™ 2019 in San Francisco

  1/3/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square.

• 

  A Look at the Year's Most and Least Successful Biotech IPOs

  1/3/2019

  Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.

• Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

  12/12/2018

  Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website